PE Tech Report


Like this article?

Sign up to our free newsletter

Adents raises EUR8.5m in additional funding

Adents, a product unit identification and traceability software provider, has secured EUR8.5 million in additional funding. 

This round of financing will allow the fast-growing company to expand its international presence and ensure the rapid deployment of its software solution on pharmaceutical product packaging lines in Europe and North America.
Founded in 2007, Adents has quickly become a major player in product unit identification and traceability software in France, particularly in the pharmaceutical sector.
In a context where counterfeit medicines are flooding the internet and arrive at the pharmacy or hospital, sometimes becoming part of the official distribution channel and putting millions of lives in danger, principal countries across the globe have passed anti-counterfeiting legislation. In order to protect patients, the pharmaceutical industry must now identify each drug pack individually using a unique code. This further step in serialisation must be implemented for the global production of prescription medicines worldwide by the end of 2018.
With over 25 years’ of experience in traceability, Adents’ founders have developed a new generation of software which allows laboratories and contract manufacturers to conform to regulations on time and in accordance with national specificities.
As the only standard serialisation solution on the market, Adents’ software offers the major advantage of fast, easy deployment while limiting disruptions to production. Today, more than one billion codes have already been generated and piloted by Adents’ software.
The capital increase of EUR8.5 million is led by existing shareholders NAXICAP Partners and CapHorn Invest, its historical shareholders, Omnes Capital and members of the management team. The funding will allow Adents to support its continued growth in Europe and North America, where the company has just opened two subsidiaries: Adents Canada Inc. and Adents US Inc.
“These funds will allow us to establish a presence in major European countries. We are going to be in a position to meet the needs of the pharmaceutical industry picking up speed with approaching regulation deadlines,” says Christophe Devins, Adents CEO and co-founder.
“Adents has developed a mature and unique technology which enables the pharmaceutical industry to comply with the new worldwide legislations. The software company is in a very good position to become a global leader on a market which represents several billion euros globally,” adds Michel de Lempdes, Managing Director, Omnes Capital.

Like this article? Sign up to our free newsletter